Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection (NIRVANA)

Study at a Glance

Estimated Time Commitment


18 years to 101 years

Diagnosis Required

SARS-CoV-2 Infection with Acute Kidney Injury

Diseases Being Studied

Location: University Hospital

The purpose of the NIRVANA study is to determine if nicotinamide riboside is safe and whether it increases blood NAD+ levels (energy production) and improves or protects kidney function in hospitalized patients with COVID-19 infection and acute kidney injury.

Location: University Hospital

Meet Your Clinical Research Team

Contact us

Principal Investigator: Dr. Kumar Sharma; Sponsor: NIH-NIDDK

Dr. Kumar Sharma; Sponsor: NIH-NIDDK